The Achilles injury only briefly interrupted the honors for Stewie.
The US space agency is ready to attempt the first powered, controlled flight on another planet.
George W. Bush said that it's a "problem" Americans have a hard time imagining bipartisan bonds like the one he and Michelle Obama share
The look arrives in May.
SAN FRANCISCO, April 18, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Ebix, Inc. (NASDAQ: EBIX) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Nov. 9, 2020 – Feb. 19, 2021Lead Plaintiff Deadline: April 23, 2021Visit: www.hbsslaw.com/cases/EBIXContact An Attorney Now: EBIX@hbsslaw.com 844-916-0895 Ebix, Inc. (EBIX) Securities Fraud Class Action: The complaint alleges that Defendants concealed that: (1) there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix’s gift card business in India during 4Q 2020; (2) that there was a material weakness in Company’s internal controls over the gift or prepaid revenue transaction cycle; and (3) that the Company’s independent auditor, RSM, was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel. Investors began to learn the truth on Feb. 19, 2021 when RSM abruptly resigned, stating that that “despite repeated inquiries” RSM was unable to obtain sufficient audit evidence to “evaluate the business purpose of significant unusual transactions that occurred in the fourth quarter of 2020, including whether such transactions have been properly accounted for and disclosed in the financial statements subject to the Audit.” These “unusual transactions” concerned the company’s gift card business in India. In addition, RSM and Ebix reportedly disagreed over whether $30 million transferred to a comingled trust account of Ebix’s outside counsel should still be classified as cash on Ebix’s balance sheet, even though those funds were outside Ebix’s direct control. On this news, the Company’s share price fell as much as $20.24, or 40%, in a single trading day. On Mar. 8, 2021, Ebix announced it has retained KG Somani & Co. as its new auditor, that it would not file its annual report until Apr. 2021, and that Board-appointed consultants and outside legal counsel are continuing “to evaluate the payment solutions business.” Most recently, on Mar. 11, 2021, the Company received a noncompliance letter from Nasdaq for failing to timely file its 10-K, demanding that EBIX submit a plan to regain compliance with Nasdaq’s rules by Apr. 16. “We’re focused on investors’ losses and proving Ebix insiders cooked the company’s books,” said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in Ebix shares and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman. Whistleblowers: Persons with non-public information regarding Ebix should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email EBIX@hbsslaw.com. About Hagens BermanHagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw. Contact: Reed Kathrein, 844-916-0895
(Washington Capitals) with a Goalie Save from Boston Bruins vs. Washington Capitals, 04/18/2021
A shooting at a tavern in Wisconsin killed three people and seriously injured two others early Sunday, a sheriff’s department official said.
Pakistan's foreign minister has welcomed mediation efforts by the United Arab Emirates between his country and India but told UAE newspaper Khaleej Times that he was not planning to meet his Indian counterpart in the country. Pakistani Foreign Minister Shah Mehmood Qureshi and Indian Foreign Minister Subrahmanyam Jaishankar are visiting the Gulf state at the same time.
Apr. 18—The Lady Patirots (4-7) had just five hits, but still rolled to a 17-2 three-inning win over Holmes on Saturday in Richmond. Model scored six times in both of the first two innings. Hannah Smith started in the circle and went two innings, allowing two hits, one run and three walks with three strikeouts. Piper Moore pitched the final inning, allowing one hits and one run with two ...
Apr. 18—Athletes from Madison County posted a total of 23 top-10 finishes — including four first-place performances — at the AJ's Heart of the Bluegrass Track Classic on Saturday in Mercer County. Madison Central's Ciara O'Shea took the first in the 1,600-meter run (5:04.72) and was second in the 800-meter run, while teammate Kaitlyn Cain (11-01.00) won the pole vault competition and was ...
Three people were pronounced dead at the scene of a shooting Sunday in Northwest Austin and a manhunt was underway for the killer, authorities said.
(Washington Capitals) with a Goal from Boston Bruins vs. Washington Capitals, 04/18/2021
Israeli military intelligence and senior officials in the Mossad briefed a meeting of the nation's security cabinet that talks in Vienna between Iran and other world powers will lead to the U.S. returning to the 2015 nuclear deal, two officials who attended the meeting told me.Why it matters: The Israeli government is very concerned about a U.S. return to the nuclear deal and is trying to convince the Biden administration not to take the pressure off the Iranian regime.Get market news worthy of your time with Axios Markets. Subscribe for free.Driving the news: The Mossad mainly briefed the cabinet meeting on the status of the Iranian nuclear program. Military intelligence officials discussed Iranian actions in the region at the meeting.The two intelligence agencies gave similar assessments on where the Vienna talks stand.What they are saying: “We are not very optimistic to say the least," a senior Israeli official who attended the meeting told me. "We will not be surprised if within weeks the U.S. and other world powers sign a deal with Iran.”National Security Advisor Jake Sullivan told "Fox News Sunday" that the Vienna talks with Iran were "constructive" and that there is a real effort to get back to mutual compliance of the 2015 nuclear deal. Sullivan added that the U.S. won’t lift sanctions unless it has "clarity and confidence" that Iran will fully return to compliance of all its obligations under the 2015 agreement.What’s next: Israeli officials told me there were no new policy decisions made during today’s cabinet meeting, and Israel will continue the dialogue with the Biden administration on the negotiations with Iran.In the coming two weeks the Israeli national security adviser Meir Ben Shabbatt, IDF chief of staff Aviv Kochavi, head of Israeli military intelligence Tamir Hayman and Mossad director Yossi Cohen will visit Washington for talks with their counterparts on Iran, officials tell me.More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free
(Boston Bruins) with a Shorthanded Goal from Boston Bruins vs. Washington Capitals, 04/18/2021
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 pointsImprovement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 points Improvement in cardiac function for all 7 evaluable patients demonstrated by a decrease in global longitudinal strain (GLS) Emerging Science Oral Presentation today at AAN 2021 DUBLIN, Ireland, April 18, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting. PRX004 showed favorable results as demonstrated by slowing of neuropathy progression for all 7 evaluable patients at 9 months, including improvement in neuropathy in 3 of the 7 patients, and improved cardiac systolic function for all 7 patients. In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels. The positive results were presented by Dr. Ole Suhr, Senior Professor, Department of Public Health and Clinical Medicine, Umeå University, gastroenterologist and internist who was a principal investigator in the study and were previously highlighted by Prothena on December 9, 2020. For all of the evaluable patients, slowing of neuropathy progression was demonstrated by a mean change from baseline in Neuropathy Impairment Score (NIS) of +1.29 points at 9 months. This compares favorably to a calculated mean change in NIS of +9.2 points at 9 months in untreated and placebo-treated patients with hereditary ATTR peripheral neuropathy (hATTR-PN) based on analysis of published historical data. In addition, the change in NIS for each of these evaluable patients was more favorable than the published historical data. In this highly progressive disease, it was encouraging to see 3 of 7 patients demonstrate improvement in neuropathy with a mean change in NIS of –3.33 points at 9 months. These positive results were observed in patients with or without concomitant use of stabilizer therapy. PRX004 also demonstrated improvement in cardiac systolic function in each of the 7 evaluable patients, with a mean change in GLS of –1.21% at 9 months (centrally read). For the 3 patients who improved on NIS, GLS improvement was more pronounced, with a mean change of –1.51% at 9 months. Taken together, these positive clinical findings suggest PRX004’s depleter mechanism of action can result in benefits in both neuropathy and cardiac function. “I was pleased to see evidence of both a slowing of disease progression as well as a rapid improvement in neuropathy in some patients after only 9 months of treatment with PRX004. Given the expected clinical progression in these patients, the more favorable than expected change in NIS for all 7 patients is an encouraging finding, as is PRX004’s favorable safety and tolerability profile,” stated Ole Suhr, MD. “These results demonstrate the potential of PRX004’s depleter mechanism to provide a new treatment paradigm that is highly needed to treat patients at high risk of early mortality due to amyloid deposition in vital organs.” Today’s presentation at AAN 2021 will be made available on the Company’s website at www.prothena.com under the Investors tab in the Events and Presentations section. PRX004 Phase 1 Study The Phase 1, open-label, multicenter dose-escalation study (NCT03336580) enrolled 21 patients with hereditary ATTR Amyloidosis (hATTR) to receive PRX004 intravenously once every 28 days for up to 3 infusions in the dose escalation phase of the study. Patients were enrolled into 1 of the following 6 PRX004 dose cohorts: 0.1, 0.3, 1, 3, 10, and 30 mg/kg, starting with the lowest dose. Eligible patients who completed dose-escalation were provided the opportunity to enroll in the long-term extension (LTE) portion of the study. All 21 patients enrolled in the Phase 1 study successfully completed dose-escalation and 17 patients subsequently enrolled in the LTE. In order to inform dose selection, a pharmacokinetic/pharmacodynamic (PK/PD) model was developed and subsequently confirmed by observed reductions in free non-native TTR (transthyretin) in plasma of patients following PRX004 administration. Based on this model, dose levels ≥3 mg/kg were predicted to saturate (occupy ≥90%) amyloid deposits. Therefore, cohorts 4, 5 and 6 were considered equivalent, and efficacy was explored in these patients and pooled. Of the 12 patients in these cohorts, 7 patients (n=3 in cohort 4, n=3 in cohort 5 and n=1 in cohort 6) received all infusions through 9 months and were therefore considered evaluable for efficacy. The remaining 5 patients did not meet these criteria due to COVID-19 pandemic-related disruptions. PRX004 demonstrated a PK profile consistent with an lgG1 monoclonal antibody and exposures increased proportionally with dose. Monthly intravenous (IV) infusions of PRX004 were generally safe and well tolerated at all dose levels tested, with 233 separate infusions and up to 17 infusions per patient in the study. No drug-related serious adverse events (SAEs), drug-related ≥ grade 3 adverse events, deaths or dose-limiting toxicities were reported. The most frequent treatment-emergent AEs (≥10%) were fall, anemia, upper respiratory tract infection, back pain, constipation, diarrhea and insomnia. No clinically relevant anti-drug antibodies were observed. Consistent with the proposed mechanism of action, PRX004 administration did not impact levels of native, normal tetrameric TTR. About ATTR Amyloidosis Transthyretin amyloidosis (ATTR amyloidosis) is a rare, progressive and fatal disease characterized by deposition of abnormal, non-native forms of TTR protein (amyloid) in vital organs. ATTR amyloidosis can be hereditary (hATTR) when caused by a mutation in the TTR gene, or wild-type (wtATTR) when it occurs sporadically. Patients can experience a spectrum of clinical manifestations due to deposition of amyloid that can affect multiple organs, most commonly the heart and/or nervous system. It is estimated that between 400,000 to 1.4 million patients suffer from ATTR-cardiomyopathy (ATTR-CM). Within this population, between 130,000 to 490,000 patients are estimated to be moderate-to-advanced and categorized as New York Heart Association Class III and IV. TTR protein is produced primarily in the liver, pancreas and choroid plexus and in its native tetrameric form serves as a carrier for thyroxin and retinol binding protein (a transporter for vitamin A) and has been proposed to have neuroprotective effects. About PRX004 and Depleter Mechanism of Action PRX004 is an investigational humanized monoclonal antibody designed to deplete amyloid associated with disease pathology that underlies hereditary and wild type ATTR amyloidosis (hATTR and wtATTR, respectively), without affecting the native, normal tetrameric form of the protein. It is generally accepted that at the time of diagnosis, affected organs in ATTR patients contain extracellular amyloid deposits. These deposits, together with prefibrillar species, are believed to cause organ dysfunction. PRX004 has been shown in preclinical studies to promote clearance of insoluble amyloid fibrils through antibody-mediated phagocytosis and inhibit amyloid formation. This depleter mechanism of action has the potential to provide benefit for ATTR patients at high risk for early mortality due to amyloid deposition in vital organs. About Prothena Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp. Forward-looking Statements This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design and proposed mechanism of action of PRX004; and the design and capabilities of our misTTR assay for hereditary ATTR. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the effects on our business of the worldwide COVID-19 pandemic and the risks, uncertainties and other factors described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2021, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in our expectations. Contacts: Media:Ellen Rose, Head of Communications650-922-2405, email@example.com Investors:Jennifer Zibuda, Director, Investor Relations & Communications650-837-8535, firstname.lastname@example.org
Bitcoin dropped as much as 15% overnight, its biggest intraday drop since February, just days after hitting record highs.
The blaze, in Cape Town, has burned a university library, forcing the evacuation of students.
Two men died after a Tesla vehicle, which was believed to be operating without anyone in the driver's seat, crashed into a tree on Saturday night north of Houston, authorities said. “There was no one in the driver’s seat," Sgt. Cinthya Umanzor of the Harris County Constable Precinct 4 said. One of the men was in the front passenger seat while the other was in the back seat of the Tesla, the newspaper reported, the Wall Street Journal reported, citing an interview with Harris County Precinct 4 Constable Mark Herman.
The longtime co-stars shared a selfie with Anderson's dog.